Oncoloxía médica
Servizo
Hospital Universitario Puerta de Hierro
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (62)
2024
-
Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients
Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 88-94
-
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry
Lung Cancer, Vol. 190
-
Difficulties on the access to innovative targeted therapies for lung cancer in Spain
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612
-
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Clinical and Translational Oncology
-
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study
European urology oncology, Vol. 7, Núm. 3, pp. 447-455
2023
-
Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study
ERJ Open Research, Vol. 9, Núm. 6
-
Occupation as a risk factor of small cell lung cancer
Scientific Reports, Vol. 13, Núm. 1
-
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
European Journal of Cancer, Vol. 182, pp. 3-14
-
SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2732-2748
-
Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer
Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 882-896
-
Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma
Cancer, Vol. 129, Núm. 16, pp. 2581-2592
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119
-
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
Annals of Oncology, Vol. 33, Núm. 2, pp. 181-192
-
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
BMC Cancer, Vol. 22, Núm. 1
-
Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain
Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 495-502
-
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)
Journal of Clinical Oncology, Vol. 71
-
SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)
Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 703-711
-
SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021)
Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 613-624
-
SEOM—GECOD clinical guideline for unknown primary cancer (2021)
Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 681-692
-
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
Journal for immunotherapy of cancer, Vol. 10, Núm. 9